Cointime update: Grand Pharma has completed enrollment of the first patient in a Phase II clinical trial in China for GPN01020, a Class 1.1 traditional Chinese medicine innovative drug for migraine prevention. The company called the milestone a key step for its otolaryngology Chinese patent medicine portfolio, marking the transition of the hospital-formulation-derived drug from long-term clinical experience into evidence-based validation.
Grand Pharma’s Migraine Prevention TCM Drug GPN01020 Doses First Patient in Phase II Trial
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
6m ago
Perpetual DEX Variational Raises $110M at $1.5B Valuation
1h ago
Zcash Spot ETF Filed by Bitwise for Texas Stock Exchange Listing
1h ago
Largest Anthropic Short on Hyperliquid Grows to About $93.76M
1h ago
Blockaid: K3 Capital sBOLD Vault Exploited, $3.43M Drained
1h ago
KuPool Launches Bitcoin Mining Service, Now Supports BTC, DOGE/LTC and ZEC
1h ago
BlackRock Moves $315M in BTC and ETH to Coinbase Prime